Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients

被引：102

作者：

Savès, M

Raffi, F

Clevenbergh, P

Marchou, B

Waldner-Combernoux, A

Morlat, P

Le Moing, V

Rivière, C

Chêne, G

Leport, C

机构：

[1] INSERM, U330, F-33076 Bordeaux, France

[2] Hop Hotel Dieu, CISIH, F-44035 Nantes, France

[3] Hop Archet, Serv Malad Infect & Trop, F-06202 Nice 3, France

[4] Hop Purpan, Serv Malad Infect & Trop, F-31059 Toulouse, France

[5] Hop Robert Debre, Serv Malad Infect, F-51092 Reims, France

[6] Hop St Andre, Serv Med Interne, F-33075 Bordeaux, France

[7] Fac Xavier Bichat, Lab Rech Pathol Infect, F-75018 Paris, France

[8] Hop La Pitie Salpetriere, Dept Malad Infect Trop Parasitaires & Sante Publ, F-75651 Paris 13, France

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2000年 / 44卷 / 12期

基金：

英国惠康基金;

关键词：

D O I：

10.1128/AAC.44.12.3451-3455.2000

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

In a cohort of 1,047 human immunodeficiency virus type 1-infected patients started on protease inhibitors (PIs), the incidence of severe hepatic cytolysis (alanine aminotransferase concentration five times or more above the upper limit of the normal level greater than or equal to 5N) was 5% patient-years after a mean follow-up of 5 months. Only positivity for hepatitis C virus antibodies (hazard ratio [HR], 7.95; P < 10(-3)) or hepatitis B virus surface antigen (HR, 6.67; P < 10(-3)) was associated with severe cytolysis. Before starting patients on PIs, assessment of liver enzyme levels and viral coinfections is necessary.

引用

页码：3451 / 3455

页数：5